Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,897 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07595835RecruitingPhase 1/Phase 2
Radioactive particles injected into pancreatic tumors
This trial tests a new treatment where doctors use imaging to guide radioactive particles directly into locally advanced pancreatic cancer tumors that haven't spread. The goal is to shrink or control the cancer with radiation delivered right to the tumor.
Amsterdam, North HollandAges 18 years+ - NCT06717022Recruiting
CHT102 for mesothelin-positive advanced solid tumors
This trial tests a new cell therapy called CHT102 for people with advanced solid tumors that have a certain marker (mesothelin). The treatment is for those who haven't responded to standard therapy or who don't have a standard first-line option.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05918445RecruitingPhase 1/Phase 2
PM8002 for advanced solid tumors that have stopped responding
This Phase 1/2 study tests PM8002 in people with advanced solid cancers to see if it can work and is safe. It may help if your cancer has measurable disease and you have not fully recovered from side effects of prior treatment.
BaojiAges 18–75 - NCT06016075Recruiting
Studying kidney masses with advanced MRI
This study uses advanced MRI scans to better understand the differences between non-cancerous and cancerous kidney growths. It may help doctors improve how they diagnose and treat kidney masses.
Cambridge, CambridgeshireAges 18 years+ - NCT06718205RecruitingPhase 2
Nimotuzumab plus immunotherapy and chemo for esophageal cancer
This study tests a new combination of drugs for advanced esophageal cancer. It adds an antibody (nimotuzumab) and an immunotherapy (sintilimab) to standard chemotherapy, aiming to improve how well treatment works.
Zhengzhou, HenanAges 18–75 - NCT06718738RecruitingPhase 1
IM96 CAR-T for advanced colorectal cancer
This trial tests a new cell therapy called IM96 CAR-T, which targets a protein (GUCY2C) found on tumor cells. It is for people with advanced colorectal or stomach cancer that has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Los Angeles, CaliforniaAges 1–21 - NCT07591155RecruitingPhase 1
Testing BL-ARC002 for advanced solid tumors
This early-stage trial tests a new cancer drug called BL-ARC002 in patients whose advanced or spread cancers (solid tumors) have not responded to standard treatments. The drug is an antibody designed to help the immune system fight cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07589517RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Colorectal Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to fight advanced colorectal cancer that has spread or cannot be surgically removed. The therapy is customized to target specific protein markers on your cancer cells.
Shenzhen, GuangdongAges 18–75 - NCT07590531RecruitingPhase 1/Phase 2
Two-Drug Lung Cancer Treatment Study
This trial tests a combination of two experimental drugs (AMT-116 and ivosidan) for patients with advanced lung cancer that cannot be removed by surgery. The study aims to see if this combination can help shrink tumors and improve survival.
Guangzhou, GuangdongAges 18–75 - NCT07589205RecruitingPhase 1
Testing IBI3028 for Advanced Solid Tumors
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07589244RecruitingPhase 2/Phase 3
VRT106 with Camrelizumab and Apatinib for Advanced Liver Cancer
This study tests a combination of three drugs—VRT106 (a new oncolytic virus therapy), camrelizumab (an immune-boosting drug), and apatinib (a targeted cancer drug)—to treat advanced hepatocellular carcinoma (HCC), a type of liver cancer. The goal is to see if this combination works better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT07593092RecruitingPhase 1
Testing new cancer immunotherapy for advanced ovarian cancer
This study tests two new experimental drugs (XmAb541 and XmAb808) designed to fight advanced ovarian cancer by activating your immune system. You'll be closely monitored to see how safe the drugs are and how your body tolerates them.
Lake Success, New YorkAges 18 years+ - NCT07594925RecruitingPhase 2
Short-course radiation plus immunotherapy and chemotherapy for rectal cancer
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
TianjinAges 18–75 - NCT07593820RecruitingPhase 1
CAR-T Cell Study for Advanced HER2-Positive Cancers
This early-stage trial tests a new type of immune cell therapy called CAR-T cells, which are designed to recognize and attack cancer cells that have a protein called HER2. The cells are made from your own immune cells, trained in the laboratory, and given back to you. The study evaluates how safe the treatment is and whether it can shrink tumors.
Barcelona, CataloniaAges 18 years+ - NCT07578571RecruitingPhase 1
Testing a New Cancer Treatment Called IM-1617
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
New Haven, ConnecticutAges 18 years+ - NCT07584954RecruitingPhase 1
Testing a new cancer immunotherapy in advanced solid tumors
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
Fuzhou, FujianAges 18–75 - NCT07582315RecruitingPhase 3
BL-B01D1 for advanced biliary tract cancer after prior treatments
This study tests a new drug called BL-B01D1 against standard treatment options for patients with advanced biliary tract cancer (cancer of the bile ducts) that has stopped responding to platinum chemotherapy and immunotherapy. The drug is designed to target and destroy cancer cells more effectively.
Beijing, Beijing MunicipalityAges 18–75 - NCT07586124RecruitingPhase 2
Immunotherapy plus antibody drug for advanced head and neck cancer
This trial tests a combination of two drugs (pucotenlimab and becotatug vedotin) given before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve outcomes when combined with surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07579221RecruitingPhase 1/Phase 2
Navlimetostat and Pumitamig for Advanced Lung Cancer
This study tests a combination of two experimental drugs (navlimetostat and pumitamig) for advanced non-small cell lung cancer in patients whose tumors have a specific genetic change called MTAP loss. The drugs are designed to attack cancer cells in a new way and may help patients whose cancer has stopped responding to previous treatments.
Houston, TexasAges 18 years+ - NCT07584824Recruiting
Cancer Care Laws and Modern Technology Survey
This survey asks cancer patients, their relatives, and healthcare workers in the UK about how well current cancer care laws work with today's technology. Your feedback helps shape future cancer care policies and practices.
TruroAges 18 years+ - NCT07582887Recruiting
Genetic Testing to Predict Side Effects from Breast Cancer Antibody Drugs
This study examines how genetic differences affect how your body handles three newer breast cancer medications (Sacituzumab Govitecan, Trastuzumab Deruxtecan, or Datopotamab Deruxtecan). A blood test will check your UGT1A1 gene to help doctors predict which side effects you might experience and adjust your treatment accordingly.
Granada, GranadaAges 18 years+ - NCT07583654RecruitingPhase 1
Testing a New mRNA Cancer Treatment for Advanced Solid Tumors
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
Chengdu, SichuanAges 18–70 - NCT06124963RecruitingPhase 2
WX390 plus Toripalimab for STK11-mutated cervical cancer
This trial tests a combination of an experimental pill (WX390) and an immunotherapy drug (Toripalimab) for a specific type of cervical cancer that has an STK11 gene change. It aims to see if this combination can shrink tumors or slow the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,897 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.